Christopher L. Brooks
Plus aucun poste en cours
Profil
Dr. Christopher L.
Brooks is a Director-Preclinical Development at Stemline Therapeutics, Inc.
He received his undergraduate degree from the State University of New York at Binghamton and a doctorate degree from Columbia University.
Anciens postes connus de Christopher L. Brooks
| Sociétés | Poste | Fin |
|---|---|---|
| STEMLINE THERAPEUTICS, INC. | Corporate Officer/Principal | - |
Formation de Christopher L. Brooks
| State University of New York at Binghamton | Undergraduate Degree |
| The Trustees of Columbia University in The City of New York | Doctorate Degree |
Expériences
Fonctions occupées
Actives
Inactives
Sociétés cotées
Entreprise privées
Sociétés liées
| Entreprise privées | 1 |
|---|---|
Stemline Therapeutics, Inc.
 Stemline Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Stemline Therapeutics, Inc. is a clinical stage biopharmaceutical company, which engages in the discovery, acquisition, development, and commercialization of novel therapeutics for oncology indications of unmet medical need. Its clinical stage product candidates include SL-401, SL-801, and SL-701. The SL-401, is a targeted therapy directed to the interleukin-3 receptor (CD123) present on a malignancies. The SL-801, is a novel oral small molecule reversible inhibitor of XPO1, that has demonstrated in vivo and in vitro preclinical activity in solid and hematologic malignancies. The SL-701, is an immunotherapy designed to activate the immune system to attack tumors. The company was founded by Ivan Bergstein on August 8, 2003 and is headquartered in New York, NY. | Health Technology |
